INTERNATIONAL PATENT: GENENTECH, INC. FILES APPLICATION FOR "DOSAGE REGIMEN FOR REDUCING CYTOKINE RELEASE SYNDROME (CRS) WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA THERAPY"

GENEVA, Feb. 11 -- GENENTECH, INC. (1 DNA WaySouth San Francisco, CA 94080-4990) filed a patent application (PCT/US2025/039903) for "DOSAGE REGIMEN FOR REDUCING CYTOKINE RELEASE SYNDROME (CRS) WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA THERAPY" on Jul 30, 2025. With publication no. WO/2026/030464, the details related to the patent application was published on Feb 05, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): WONG, Chihunt (c/o Genentech, Inc.1 DNA WaySouth San Francisco, CA 94080-4990), COOPER, James, Niall (c/o Genentech, Inc.1 DNA WaySouth San Francisco, CA 94...